Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma

Inclusion Criteria:

* older than 18 years,
* male or female,
* diagnosis of secondary liver cancer or cholangiocarcinoma based on positive biopsy or noninvasive criteria,
* presence of at least one lesion untreatable by surgical resection or ablation for microwave or radio frequency,
* the target nodule must have a diameter of ≤ 5 cm
* ECOG score(Eastern Cooperative Oncology Group) 0,
* ASA score (American Society of Anesthesiologists) ≤ 3,
* prothrombin time ratio \>50%
* platelet count \>50x10\^9/l,
* patient's ability to discontinue anticoagulant and antiplatelet therapy for seven days before and seven days after surgery with NanoKnife™,
* ability to understand and willingness to sign the written informed consent form (ICF),
* life expectancy of at least 3 months.

Exclusion Criteria:

* presence of more than 5 liver lesions,
* previous treatment of the target nodule,
* patient received systemic chemotherapy within 30 days of treatment with the IRE NanoKnife™,
* heart failure, coronary artery disease or arrhythmia in progress, active implantable devices (eg pacemaker),
* pregnant women or women of childbearing potential not using an acceptable method of contraception,
* patient undergoing treatment with an investigational drug within 30 days of treatment with the IRE NanoKnife™,
* in the opinion of the researcher, anyone who can not follow the calendar of visits and assessments of the Protocol.